Upstream Bio, Inc. (UPB) — Cash Flow-to-Debt Ratio
Upstream Bio, Inc. (UPB) has a Cash Flow-to-Debt Ratio of -1.76x as of September 2025, meaning its operating cash flow of $-22.24 Million could theoretically repay -2% of its total liabilities ($12.61 Million) in one year. See working capital position of Upstream Bio, Inc. to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Upstream Bio, Inc. Cash Flow-to-Debt Ratio (2022–2024)
Historical debt coverage capacity for Upstream Bio, Inc. across 3 annual periods. Also explore Upstream Bio, Inc. equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Upstream Bio, Inc. (2022–2024)
Year-by-year debt coverage analysis for Upstream Bio, Inc.. For market capitalisation and broader financial context, see UPB market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -4.99x | $-59.17 Million | $11.87 Million | ▼ -3059.6% |
| 2023 | -0.16x | $-37.93 Million | $240.32 Million | ▼ -3.4% |
| 2022 | -0.15x | $-19.02 Million | $124.63 Million | — |